The kinetics of mast cell accumulation in the nasal mucosa during allergen exposure were investigated in the animal model of experimentally induced allergic rhinitis. Guinea-pigs were divided into an unsensitized control group and five sensitized groups each containing five animals. Five sensitized groups were immunized intraperitoneally with ovalbumin, followed by intranasal administration of ovalbumin in each of four groups for 1, 2, 3 and 4 weeks, respectively. There were significant increases in the number of mast cells in the epithelium after 2 and 3 weeks in the groups receiving intranasal ovalbumin. No significant changes were detected in the lamina propria and the total number of mast cells. In the lamina propria, the distance between a mast cell and the basement membrane was significantly decreased in the groups after 2, 3 and 4 weeks of intranasal administration. These findings suggest that an infiltration of mast cells from the lamina propria to the epithelium occurred after 2 weeks of intranasal administration of allergen. An electron microscopic study showed no mast cells at the luminal surface of the epithelium and the majority of mast cells lying around the basal cells. This finding suggests that the allergen must penetrate into the epithelium in order to interact with mast cells in guinea-pig nose.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2222.1994.tb00225.x | DOI Listing |
Sci Adv
January 2025
Department of Chemistry, Stanford University, Stanford, CA 94305, USA.
Tigilanol tiglate (EBC-46) is a selective modulator of protein kinase C (PKC) isoforms that is Food and Drug Administration (FDA) approved for the treatment of mast cell tumors in canines with up to an 88% cure rate. Recently, it has been FDA approved for the treatment of soft tissue sarcomas in humans. The role of EBC-46 and, especially, its analogs in efforts to eradicate HIV, treat neurological and cardiovascular disorders, or enhance antigen density in antigen-targeted chimeric antigen receptor-T cell and chimeric antigen receptor-natural killer cell immunotherapies has not been reported.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Single-cell RNA sequencing (scRNA-seq) is a valuable tool for investigating cellular heterogeneity in diseases such as equine asthma (EA). This study evaluates the HIVE™ scRNA-seq method, a pico-well-based technology, for processing bronchoalveolar lavage (BAL) cells from horses with EA. The HIVE method offers practical advantages, including compatibility with both field and clinical settings, as well as a gentle workflow suited for handling sensitive cells.
View Article and Find Full Text PDFScand J Med Sci Sports
February 2025
Sports Performance Laboratory, School of Physical Education and Sport Science, National and Kapodistrian University of Athens, Athens, Greece.
The purpose of the study was to investigate the effects of exercise training on the bone marrow immune microenvironment and on minimal residual disease of multiple myeloma patients who completed first-line induction treatment. Eight multiple myeloma patients underwent 5 months of exercise training along with standard medical treatment. Eight age- and sex-matched patients who received medical treatment only, served as controls.
View Article and Find Full Text PDFCells
January 2025
European Center for Angioscience (ECAS), Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Hyaluronan (HA) levels are dynamically regulated homeostatically through biosynthesis and degradation. HA homeostasis is often perturbed under disease conditions. HA degradation products are thought to contribute to disease pathology.
View Article and Find Full Text PDFCells
January 2025
Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, #222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
Cannabinoid compounds have potential as treatments for a variety of conditions, with cannabigerol (CBG) being known for its anti-inflammatory properties. In this study, we investigated the effects of CBG in a cellular model of 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis (AD). In the cellular model, we confirmed the cytotoxicity of CBG and downregulated the expression of inflammatory markers , , , and ( < 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!